

THE EXTENT OF THE USE OF MEDICINES USED IN HYPERTENSIVE CRISIS AND THE RELEVANCE OF THEIR IMPROVEMENT

Sokhib Rashidov Zamon ugli

Abrorbek Pirmanov Akbarali ugli

Department of pharmacology of the Tashkent State Medical University

https://doi.org/10.5281/zenodo.18618191

ARTICLE INFO

Qabul qilindi: 31-yanvar 2026 yil
Ma'qullandi: 6-fevral 2026 yil
Nashr qilindi: 10-fevral 2026 yil

KEY WORDS

Hypertension, target organ damage, hypertensive emergency, hypertensive urgency, hypertensive crisis, treatment approach.

ABSTRACT

A significant rise in BP coupled with acute, A-HMOD to the heart, brain, retina, kidneys, and major arteries characterizes hypertensive emergencies (HE), which are high cardiovascular risk circumstances. Since blood pressure readings by themselves cannot reliably indicate the existence of HE, the first line of treatment for acute severe hypertension should be to look for A-HMOD. To reduce the risk of complications, enhance patient outcomes, and limit and encourage the regression of end-organ damage, a prompt therapeutic intervention is essential. The kind of A-HMOD, particular drug pharmacokinetics, adverse drug effects, and comorbidities all influence drug therapy for HE, target blood pressure, and the rate at which blood pressure decreases. Consequently, a customized strategy is necessary. For the majority of HE, there is currently insufficient evidence to support effective treatment approaches. In addition to reviewing contemporary pharmacological approaches, this article offers a methodical, evidence-based approach to the treatment of HE. The treatment of acute hypertension differs based on the presentation and local expertise and available resources. There is frequently a dearth of high-quality evidence, or when it does exist, it does not consistently support certain medication regimens or rates of blood pressure reduction. Finally, after speaking with the BIHS and considering the available evidence as well as any areas where there was disagreement, comments were made. A uniform, evidence-based approach to provide high-quality care to patients is the aim of the proposed set of guidelines for the management of acute hypertensive conditions.

Introduction. A sudden rise in blood pressure (BP) with a systolic value greater than 180 mmHg and/or a diastolic value greater than 120 mmHg is known as a hypertensive emergency (HE), and it is frequently linked to cardiovascular, neurological, or renal damage. The current term for this organ involvement is acute hypertension mediated organ damage (A-HMOD). However, in the event of rapid increases from lower baseline blood pressure, lower thresholds may be linked to hypertensive emergencies. Unless there is acute organ injury, in which case rapid BP-lowering measures are required to reduce the ongoing damage, elevated blood pressure alone does not qualify a HE, regardless of how high the blood

pressure may be. Globally, the most common and significant modifiable risk factor for cardiovascular disease and disability is high blood pressure (BP). More than one in four persons in England suffer from high blood pressure, according to a 2015 Public Health England report. The burden of sickness is even higher in LMICs (low- and middle-income countries) [1-4]. The use of antihypertensive medications to lower the risk of cardiovascular disease and other organ damage is supported by a wealth of solid evidence. However, compared to earlier decades, acute, severe blood pressure elevations are far less frequent now. Better management and care models for chronic hypertension (HTN), particularly in industrialized nations, as well as increased screening and awareness may be to blame for this. However, hypertensive crises, which can be fatal and cause immediate end organ damage and/or death, continue to occur in patients. In patients with hypertensive crises, there is a dearth of reliable outcome data defining blood pressure objectives, the rate at which blood pressure drops, and particular drugs (NICE, 2019). A substantial part of management is based on the opinions of experts. As expected, national and international HTN guidelines frequently cover very little, and there is significant variation and inconsistency in the way severe HTN is treated in clinical practice [5-10]. Before starting anti-hypertensive medication, a number of things should be taken into account, even though it is generally acknowledged that significantly raised blood pressure must be lowered. Based on the data currently available, our goal in this position paper is to present a paradigm for the diagnosis, assessment, and treatment of patients experiencing hypertensive crisis. The brain, cardiovascular, hematologic, renovascular, and ophtalmologic systems can all experience new or worsening target organ damage. From a prognostic and therapeutic standpoint, the degree of blood pressure increase and the absolute blood pressure levels are significant, with early detection being essential. The fact that stroke accounts for 38% of all HE clinical presentations, followed by pulmonary oedema (35%), and coronary syndromes (25%), emphasizes how uncontrolled hypertension plays a significant role in all major cardiovascular events. Therefore, it is imperative that HE be recognized and treated right away. The one-year mortality rate for patients who present with HE surpasses 79% even though there is insufficient evidence to show that treating HE lowers mortality [11-16]. The kind of A-HMOD, past comorbidities, particular drug pharmacokinetics, or potential adverse drug reactions all influence the choice of therapeutic approach, including the class of antihypertensive medications and the timeframe for lowering blood pressure. Consequently, a customized strategy is necessary. For the majority of HE, there is currently insufficient evidence to support effective treatment approaches. In addition to reviewing contemporary pharmacological approaches, this article offers a methodical, evidence-based approach to the treatment of HE. Although hypertensive crises still have a high death and morbidity rate, their frequency has decreased over the past few decades. Guidelines for managing hypertensive crises have been repeatedly and updated by several scientific bodies; nonetheless, there is a lack of precise information regarding the potential impact of medication variations on morbidity and mortality among patients receiving treatment for hypertensive crises. The clinical picture and related co-morbidities determine which medicine or medications are best [17-22].

The main purpose of this brief overview of the scope of medicines used in hypertensive crisis is to analyze the relevance of their improvement based on authoritative scientific papers on modern measures.

Setting the Scene with Definition and Epidemiology. Clinical conditions linked to elevated blood pressure have been referred to by a variety of names, including hypertensive urgencies, hypertensive crises, uncontrolled hypertension, and HE. However, only the terms "HE" and "uncontrolled hypertension," which can now be used to refer to the entire clinical range of abruptly raised blood pressure, have been kept in the present language. Hypertensive emergencies are defined as circumstances in which acute, life-threatening organ damage in any of the following important organs—the brain, arteries, retina, kidney, and/or heart—

occurs in conjunction with a significantly elevated blood pressure, typically a systolic value greater than 180 mmHg and/or a diastolic value higher than 120 mmHg. Severe uncontrolled hypertension (U-HTN) is the term used to describe the remaining conditions with increased blood pressure but no A-HMOD. Given the significant variations in care and treatment, it is imperative to distinguish between these two clinical entities [5-11]. Acute coronary syndrome (ACS), acute heart failure with pulmonary oedema, acute aortic syndrome, hypertensive encephalopathy, ischemic or hemorrhagic stroke, pre-eclampsia, and eclampsia are among the clinical conditions that should be treated immediately for patients who present with HE. Pharmacological and nonpharmacological interventions for lowering blood pressure levels are ideal, particularly when intravenous medications are administered. Conversely, U-HTN typically does not cause signs of damage (A-HMOD), does not necessitate hospitalization, and is typically treated by merely restarting or stepping up already prescribed antihypertensive medication therapy. Two things should be kept in mind regardless of the reason or clinical presentation. First, there is insufficient data from randomized controlled trials to determine the best course of treatment or the appropriate medication in certain circumstances. Second, lowering blood pressure should be accomplished gradually and under supervision so as not to jeopardize organ perfusion. The higher in-hospital and out-of-hospital mortality rates among patients with HE highlight the significance of a suitable therapeutic approach. According to recent research, the 12-month death rate might range from 12% to 38.9%. Furthermore, end-organ damage is caused by elevated blood pressure, which deteriorates the long-term outlook. Therefore, in order to prevent further organ damage and enhance prognosis, a therapeutic approach to lower blood pressure must be implemented very away [25-32].

Identification of Hypertensive Emergencies via Diagnostic Work-Up. A physical examination, anamnestic information, and paraclinical evaluation—including imaging tests—should all be included in the initial assessment. In hypertensive situations, a quick and efficient examination is essential to reducing morbidity and mortality. A thorough medical history should reveal information about the severity and length of any underlying hypertension as well as whether HMOD has ever been diagnosed. Important components of the medical history include the use of illegal or over-the-counter medicines, history of blood pressure regulation, and antihypertensive medication. In order to determine whether aortic dissection is likely, blood pressure should be checked in both arms, while standing and while supine, and in both positions. Jugular venous distension, crackles, level of awareness, focal neurological symptoms, and meningeal irritation indicators should all be assessed as part of a physical examination that looks for indications of A-HMOD [17-22]. Every patient suspected of having HE will be assessed using standard tests, including a chest X-ray, electrocardiogram, complete blood count, urinalysis, and basic metabolic panel. Based on symptoms, additional targeted research should be conducted in accordance with the differential diagnosis of each related condition. According to the guidelines, ED-recommended testing is guided by specific clinical presentation; in a study evaluating 423 patients presenting with suspected HE, only 6% of the patients admitted to the ED benefited from a comprehensive and exhaustive evaluation, including fundoscopy, the most thorough evaluation being in the case of cardiovascular presentation symptoms. Magnetic resonance imaging may be required if neither is present and there is no other explanation for the altered mental status. Similarly, patients presenting with chest pain or shortness of breath should be assessed by troponin and natriuretic peptides; if acute aortic syndrome is suspected, computed tomography angiography of the thorax and abdomen is required [31-37].

Raised blood pressure definitions. Acute severe hypertension, hypertensive urgency, hypertensive emergency, malignant hypertension (MHT), accelerated phase hypertension, and hypertensive crisis are some of the terms used to characterize a significant increase in blood pressure. To minimize the risk of iatrogenic injury and to guide appropriate management, it is critical to differentiate between the major words. ***Severe acute***

hypertension. Over the past 70 years, the meaning of "severe" has gradually evolved. Although the degree of urgency varies on the specific circumstances, most doctors agree that a blood pressure reading of more than 200/120 mmHg is serious and requires immediate attention. A BP of 160/100 mmHg would be a medical (hypertensive) emergency in the context of acute end organ damage (EOD), such as preeclampsia, whereas a BP of 180/100 mmHg in a poorly adherent, uncontrolled chronically hypertensive patient would typically not be regarded as acute severe HTN requiring immediate treatment. For people who have a significant increase in blood pressure but no signs of acute or life-threatening EOD, we prefer to refer to them as having "acute severe hypertension." This group includes the majority of patients who visit emergency departments (EDs), and it can be challenging to determine whether an increase in blood pressure is acute or chronic, particularly if blood pressure hasn't been checked recently [5-11]. This subgroup is referred to as severe hypertension in the National Institute for Health and Care Excellence (NICE) guidelines (NG 136). NICE, 2019. In patients who are asymptomatic, the term "hypertensive urgency" is not always helpful because it might cause patients to experience excessive worry and raise healthcare expenses with no related morbidity. For this reason, we would rather not use it. ***An emergency involving hypertension.*** Elevated blood pressure, or hypertensive emergency, can result in gradual, potentially fatal EOD if it persists for a few hours. Acute coronary syndrome (ACS), severe preeclampsia/eclampsia, aortic dissection, intracerebral hemorrhage (ICH), acute pulmonary oedema, hypertensive encephalopathy, acute renal failure, and pheochromocytoma crisis are among its most common disorders. Although not always, blood pressure may be significantly high in a number of these diseases. In some circumstances, a slight rise in blood pressure can be potentially fatal, especially if it occurs quickly. In certain emergency situations, such as acute ischemic stroke (AIS) and subarachnoid hemorrhage (SAH), an increase in blood pressure may not be the direct cause, but it may coexist and make treatment more difficult [23-29].

An overview of global recommendations for crises with hypertension. According to the AHA/ACC and ESC/ESH guidelines, the goal of treating significantly raised blood pressure is to ensure proper follow-up while acknowledging the lack of a strong evidence foundation and to strengthen or resume oral anti-hypertensive medication therapy. In a high dependency/intensive care setting, a patient with acute EOD is often handled as a hypertensive emergency and typically receives IV anti-hypertensive treatment. However, there are differences in how patients with acute severe hypertension are managed and how quickly blood pressure drops in different situations. Generally speaking, the guidelines use a blood pressure threshold of 180/110–120 mmHg to identify seriously increased blood pressure. We disagree because there cannot be a single blood pressure cutoff point that is too low to trigger EOD, and it follows that not all patients with "severely elevated BP" require prompt treatment; instead, examination should be focused on identifying and treating EOD. Treating the patient rather than the data is crucial. The BP lowering goals and rate established in various hypertensive emergency states are primarily based on expert judgment rather than solid data. It is commonly acknowledged that antihypertensive medication should be tailored to the individual's features and that the goal of treatment should be to lower blood pressure proportionately rather than to a predetermined target level [30-37].

The future. It is evident that there is a dearth of reliable clinical trial data as well as disagreements on nomenclature and how to interpret the data that is already accessible. The quality of the evidence is weakened by using BP levels as a cutoff point to decide whether a patient has a hypertensive emergency and by using terms like "hypertensive urgency." We recommend the creation of recognized, globally standardized terminology in this area. The pace at which hypertensive situations are reduced is fundamentally predicated on CPP, and there is an unmet need for the development of non-invasive, easily navigable techniques for evaluating cerebral flow in standard clinical settings. This could aid in creating customized

blood pressure goals, which would result in MAP and CPP management that is under control. The underlying genetic, cultural, and environmental factors that make people more susceptible to hypertensive episodes are less well understood. RCTs are challenging to plan and conduct because of the inherent variability in patients' presentations of hypertensive crises and reactions to treatment [21-25]. It is necessary to establish prospective international observational research, either in the form of registries or trials, in order to enhance and expand the body of data in this area. These could aid in the evaluation of current treatment approaches as well as the development of biomarkers or an epidemiologically based multivariate risk score system, which could aid in patient stratification and allow for individualized therapy. such order to fill such knowledge gaps, a multi-national registry might be established to pinpoint regions with high prevalence rates of uncontrolled hypertension and concentrate on regional studies. All things considered, any planned RCT should be realistic, pertinent, and take into account every element that could influence the risks. Last but not least, it is critical to put patients at the center of the shared decision-making process in order to prevent pharmaceutical nonadherence from the very beginning, that is, at the time of diagnosis. Perspectives vary as a patient progresses, therefore it's critical to regularly evaluate the subjective and objective factors influencing adherence in a nonjudgmental manner using the best methods available (biochemical testing is by far the most effective) in a clinical context. A number of tactics can be used, such as patient-centered solutions, pill boxes, single combination pills, frequent follow-up, and the use of reminders and smartphone apps. Without patient collaboration, it is impossible to achieve the ultimate goal of lowering the burden of cardiovascular disease brought on by uncontrolled hypertension [27-34].

Discussion. Around the world, high blood pressure (BP) is the most common and significant modifiable risk factor for cardiovascular disease and disability. Over 1 in 4 persons in England suffer with excessive blood pressure, according to a 2015 Public Health England report. Even more people suffer from the disease in low- and middle-income (LMIC) nations. Using antihypertensive medications to lower the risk of cardiovascular disease and other organ damage is supported by a wealth of strong data. On the other hand, abrupt, significant blood pressure increase is far less frequent now than it was in the past few decades. This could be ascribed to improved management and care models for chronic hypertension (HTN), particularly in wealthy nations, as well as more widespread screening and awareness. A coordinated interprofessional approach comprising emergency physicians, internists, nephrologists, cardiologists, neurologists, pharmacists, and nursing personnel is necessary to manage a hypertensive crisis [5-11]. High rates of morbidity and mortality, along with significant medical expenses, are linked to uncontrolled hypertension. Primary care physicians, such as physician assistants and nurse practitioners, are essential in monitoring blood pressure regularly and ensuring that patients follow their antihypertensive medication prescriptions. For asymptomatic patients with extremely high blood pressure who show no signs of immediate target organ damage, hospitalization is usually not recommended. To check for end-organ involvement, patients who exhibit symptoms should be thoroughly watched, and it could be necessary to confer with the right specialists. Because abrupt or severe drops in blood pressure might cause ischemia harm in vascular areas that have acclimated to chronic hypertension, blood pressure reduction must be gradual and carefully titrated. While reducing negative outcomes, an interprofessional team approach encourages coordinated care, customized treatment plans, and safe medication titration. To ensure long-term blood pressure control, all hypertensive patients should have systematic outpatient follow-up. Changes in lifestyle, such as limiting sodium intake in the food, controlling weight, engaging in regular exercise, consuming alcohol in moderation, and quitting smoking, should be highly promoted. To avoid recurrence and enhance overall prognosis, the interprofessional care team should place a strong emphasis on medication adherence and routine home blood pressure monitoring [17-25].

Conclusion. Depending on local knowledge and the resources at hand, acute hypertension care varies depending on the presentation. High-quality evidence is often lacking or, when it is present, does not always support particular drug regimens or rates of blood pressure decrease. In conclusion, comments were made after consulting with the BIHS and taking into account the evidence that was available and any areas that lacked consensus. The goal of the suggested set of guidelines for the treatment of acute hypertensive states is to provide a consistent, evidence-based method for providing patients with high-quality care.

After receiving oral pharmaceutical interventions, the majority of patients in the HTN-U group were released from the hospital within 12 hours of their stay. In addition to using more parenteral medications, those with HTN-E had spent no more than five days in the hospital. We report that oral amlodipine or cilnidipine is the most commonly used medication for treating hypertensive crises, followed by metoprolol, a selective β_2 receptor blocker, labetalol, a dual alpha (α1) and beta (β1/β2) adrenergic receptor blocker, or clonidine, an agonist of centrally acting α2 receptors. In patients with HTN-E, intravenous nitroglycerine and intravenous labetalol were frequently used. All of the commonly used medications, including amlodipine, cilnidipine, and labetalol, were found to be beneficial in lowering blood pressure, both SBP and DBP, according to the sub-group study.

References:

1. Kulkarni, S., Glover, M., Kapil, V. et al. Management of hypertensive crisis: British and Irish Hypertension Society Position document. J Hum Hypertens 37, 863–879 (2023). https://doi.org/10.1038/s41371-022-00776-9
2. Ahmed I, Alley WD, Chauhan S, et al. Hypertensive Crisis. [Updated 2025 Dec 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507701/
3. Buitenwerf E, Osinga TE, Timmers HJLM, Lenders JWM, Feelders RA, EekhoffEMW. et al. Efficacy of α-blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial. J Clin Endocrinol Metab.2020;105:2381–91.
4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
5. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
6. Kieninger M, Gruber M, Knott I, Dettmer K, Oefner PJ, Bele S, et al. Incidence of arterial hypotension in patients receiving peroral or continuous intra-arterial nimodipine after aneurysmal or perimesencephalic subarachnoid hemorrhage. Neurocrit Care. 2019;31:32–9.
7. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670
8. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01

9. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
10. Maher M, Schweizer TA, Macdonald RL. Treatment of spontaneous subarachnoid hemorrhage: guidelines and gaps. Stroke. 2020;51:1326–32.
11. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
12. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
13. Sanoev Z.I., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Hamroyev T.T. Study Of The General Pharmacological Properties Of A New Antiarrhythmic N-Deacetyllappaconitine With Oral Administration. The American Journal of Medical Sciences and Pharmaceutical Research, 3(03), 60-64. https://doi.org/10.37547/TAJMSPR/Volume03Issue03-08
14. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344–e418.
15. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820
16. Sanoev, Z.I., Djaxangirov, F.N., Sadikov, A.Z., Sagdullaev, S.S. Hamroyev T.T. Antiarrhythmic activity of N-deacetyllappaconitine when administered orally. Annals of the Romanian Society for Cell Biology,2021,25(2), 2339–2346. https://doi.org/10.37547/tajas/Volume03Issue03-06
17. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gąsecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J. 2021;6:XLVIII–LXXXIX.
18. Sokhib Rashidov Zamon o'g'li, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o'g'li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
19. Sukumar, S.; Lämmle, B.; Cataland, S.R. Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. J. Clin. Med. 2021, 10, 536.
20. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
21. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN :

2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
22. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100:753–79.
23. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
24. Venu D, Vijay S, Kavyashree A. C., Hema A. M., Vijendra R. A prospective clinical study of the pattern of drug use in the management of hypertensive crisis in a tertiary care hospital. European Journal of Cardiovascular Medicine. Volume 15 Issue 7 (July, 2025) | Pages 454 – 462. DOI : 10.61336/ejcm/25-07-80
25. Sokhib Rashidov Zamon o‘g‘li, Nilufar Ergasheva Ag’zamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
26. Rossi, G.P.; Rossitto, G.; Maifredini, C.; Barchitta, A.; Bettella, A.; Latella, R.; Ruzza, L.; Sabini, B.; Seccia, T.M. Management of hypertensive emergencies: A practical approach. Blood Press. 2021, 30, 208–219.
27. Sokhib Rashidov Zamon o‘g‘li, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Po‘latjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
28. Astarita A, Covella M, Vallelonga F, Cesareo M, Totaro S, Ventre L, et al. Hypertensive emergencies and urgencies in emergency departments: a systematic review and meta-analysis. J Hypertens. 2020;38:1203–10.
29. Sokhib Rashidov Zamon o‘g‘li, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
30. Balahura A-M, Moroi Ş-I, Scafa-Udriște A, Weiss E, Japie C, Bartoș D, Bădilă E. The Management of Hypertensive Emergencies—Is There a “Magical” Prescription for All? Journal of Clinical Medicine. 2022; 11(11):3138. https://doi.org/10.3390/jcm11113138
31. Sokhib Rashidov Zamon o‘g‘li, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
32. Galson SW, Stanifer JW, Hertz JT, Temu G, Thielman N, Gafaar T, et al. The burden of hypertension in the emergency department and linkage to care: A prospective cohort study in Tanzania. PloS One. 2019;14:e0211287.
33. Sokhib Rashidov Zamon o‘g‘li, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qo‘shbekova Ro‘zimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857

34. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:559–69.
35. Fragoulis C, Dimitriadis K, Siafi E, Iliakis P, Kasiakogias A, Kalos T, et al. Profile and management of hypertensive urgencies and emergencies in the emergency cardiology department of a tertiary hospital: a 12-month registry. Eur J Prev Cardiol. 2022;29:194–201.
36. Waldron FA, Benenson I, Jones-Dillon SA, Zinzuwadia SN, Adeboye AM, Eris E, et al. Prevalence and risk factors for hypertensive crisis in a predominantly African American inner-city community. Blood Press. 2019;28:114–23.
37. Shin JH, Kim BS, Lyu M, Kim HJ, Lee JH, Park, JK et al. Clinical characteristics and predictors of all-cause mortality in patients with hypertensive urgency at an emergency department. J Clin Med. 2021;10:4314.